C

PriceCARISMA Therapeutics

CARM

CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma’s proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.

Historical stock price chart and annual return over the past years

-73%

5 years

% Total

CARM
-23%

5 years

Annual Return

CARM